Biolase (BIOL)
(Real Time Quote from BATS)
$0.15 USD
0.00 (1.35%)
Updated Apr 26, 2024 01:32 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BIOL 0.15 0.00(1.35%)
Will BIOL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BIOL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIOL
Quest Diagnostics' (DGX) Efforts to Reduce Health Inequities
BIOL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BIOL
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
Biolase’s Strong Q4 Performance and Positive 2024 Outlook Affirm Buy Rating
12 Health Care Stocks Moving In Friday's Intraday Session
Dow Dips 200 Points; Nike Shares Fall After Q3 Results